Zoetis Plans $590 Million Companion Animal Manufacturing Facility in Georgia
Zoetis, an animal health company focused on pharmaceuticals, vaccines, and diagnostics, has announced plans to build a new manufacturing facility in Douglasville, Georgia. The $590 million project is expected to become operational in 2029.
According to the company, the site, located near Atlanta, will focus on the production of vaccines and monoclonal antibody therapies for companion animals. Zoetis estimates the facility will create approximately 100 new jobs once fully operational.
The Douglasville project is part of a broader expansion of Zoetis’ U.S. manufacturing operations. The company reports it has invested roughly $1.7 billion in domestic facilities since 2017 and plans to invest an additional $1.3 billion by 2031.
Manufacturing Expansion and Technology Focus
Zoetis has indicated that the Georgia facility is intended to function as a technology-driven manufacturing site. Planned features include advanced automation, collaborative robotics, virtual reality–based training systems, and upgraded manufacturing execution and data management platforms.
Company representatives say these technologies are designed to support efficiency, workforce training, and scalability as demand for companion animal products continues to grow.
Zoetis’ U.S. Manufacturing Footprint
With the addition of the Douglasville facility, Zoetis will operate nine manufacturing sites across six U.S. states. Existing facilities serve a range of functions, including diagnostics and biodevices in California and North Carolina, pharmaceutical production in Michigan, and vaccine and biopharmaceutical manufacturing in Illinois, Iowa, and Nebraska.
Zoetis reports employing more than 2,700 people across its U.S. manufacturing locations.
Business Context
Since the 2017 tax reform, Zoetis has expanded its domestic investment and manufacturing capacity. The company reports that its revenue increased from $5.3 billion in 2017 to $9.3 billion in 2024. It also states that the majority of its intellectual property and global manufacturing operations are based in the United States.
Zoetis supplies animal health products to more than 100 international markets and has identified itself as a net exporter. The company has indicated that a significant portion of its U.S. sales is tied to domestically manufactured products.
Regional and Industry Implications
Large-scale manufacturing investments such as the Douglasville project reflect continued growth in the companion animal health sector, particularly in biologics and vaccine development. For the Georgia region, the facility represents a long-term economic investment, though full employment and operational impact will not be realized until later in the decade.
As demand for advanced veterinary therapeutics increases, expansions like this highlight the ongoing shift toward U.S.-based production and specialized manufacturing infrastructure within the animal health industry.
